StocktoriaREVELATION BIOSCIENCES, INC. REVB
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-10.76
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$9.1M | -$8.0M | -$8.7M | -$10.9M | -$12.0M |
| Net income | -$8.9M | -$15.0M | -$120,254 | -$10.8M | -$12.0M |
| Operating cash flow | -$8.3M | -$18.3M | -$7.3M | -$11.2M | -$11.1M |
| Free cash flow | — | -$18.3M | — | — | -$11.2M |
| Total assets | $11.6M | $6.6M | $12.2M | $5.5M | $2.0M |
| Total liabilities | $2.7M | $1.9M | $5.6M | $4.5M | $2.1M |
| Shareholders' equity | $8.9M | $4.7M | $6.6M | $1.1M | -$99,470 |
| Ratios | |||||
| Return on assets | -77.0% | -227.1% | -1.0% | -196.8% | -587.0% |
| Return on equity | -100.6% | -319.4% | -1.8% | -1029.0% | 12050.7% |
| Current ratio | 5.41 | 3.43 | 2.18 | 1.22 | 0.89 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -10.76 (distress)
- Working capital / assets 0.761
- Retained earnings / assets -4.267
- EBIT / assets -0.783
- Equity / liabilities 3.255
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001810560 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.